Amendment USSN: 10/722,703 Attorney Docket R0085D CON

CLAIM LISTING:

Claims 1-59 (Canceled)

60. (Original) A compound of the Formula I

$$R^1$$
 R^2
 R^3
 R^3

or a pharmaceutically acceptable salt thereof, wherein:

X¹ is O, NR⁴ (where R⁴ is hydrogen or alkyl), S, or CR⁵R⁶ (where R⁵ and R⁶ are independently hydrogen or alkyl) or C=O;

Arl is aryl or heteroaryl;

 R^2 is hydrogen alkyl, acyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkylcarbonyl, heteroalkyloxycarbonyl or $-R^{21}-R^{22}$ where R^{21} is alkylene or -C(=0)- and R^{22} is alkyl or alkoxy;

R¹ is hydrogen, alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkyl, heteroaralkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclylalkyl, R¹²-SO₂-heterocycloamino (where R¹² is haloalkyl, aryl, aryalkyl, heteroaryl or heteroaralkyl), -Y¹-C(O)-Y²-R¹¹ (where Y¹ and Y² are independently either absent or an alkylene group and R¹¹ is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), (heterocyclyl)(cycloalkyl)alkyl or (heterocyclyl)(heteroaryl)alkyl; and

R³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, alkylene-C(O)-R³¹ (where R³¹ is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), amino, monoalkylamino, dialkylamino or NR³²-Y³-R³³ (where Y³ is -C(O), -C(O)O-, -C(O)NR³⁴, S(O)₂ or S(O)₂NR³⁵; R³², R³⁴ and R³⁵ are independently

HALLR6 # 139547 v1 2 R0085D CON

Amendment USSN: 10/722,703

Attorney Docket R0085D CON

hydrogen or alkyl; and R³³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl or optionally substituted phenyl) or acyl.

- 61. (Original) The compound of Claim 1, wherein Ar¹ is optionally substituted phenyl.
 - 62. (Original) The compound of Claim 61, wherein X¹ is O or CH₂.
 - 63. (Original) The compound of Claim 62, wherein X^1 is O.
- 64. (Original) The compound of Claim 63 wherein R¹ is aryl, aralkyl, cycloalkyl, cycloalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, heterocyclyl or heterocyclylalkyl.
- 65. (Original) The compound of Claim 64, wherein R¹ is heteroalkylsubstituted cycloalkyl, heteroalkyl, heteroalkyl or heterocyclyl.
 - 66. (Original) The compound of Claim 65, wherein R¹ is heterocyclyl.
 - 67. (Original) The compound of Claim 65, wherein R¹ is heteroalkyl.
 - 68. (Original) The compound of Claim 67, wherein R¹ is hydroxyalkyl.
- 69. (Original) The compound of Claim 65, wherein Ar¹ is 2-substituted-phenyl, 4-substituted-phenyl or 2,4-disubstituted-phenyl.
- 70. (Original) The compound of Claim 69, wherein Ar¹ is 2-chlorophenyl, 2-fluorophenyl, 2-fluoro-4-methylphenyl, 4-fluoro-2-methyl or 2,4-difluorophenyl.
 - 71. (Original) The compound of Claim 70, wherein R³ is methyl.

HALLR6 # 139547 v1

3

R0085D CON

BEST AVAILABLE COPY

PACE 5/33 * RCVD AT 6/13/2006 9:10:04 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/27 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):15-56

Amendment USSN: 10/722,703 Attorney Docket R0085D CON

- 72. (Original) The compound of Claim 71, wherein R¹ is heteroalkyl substituted cycloalkyl, heteroalkyl, heteroalkyl, heteroalkyl or heterocyclyl.
- 73. (Original) The compound of Claim 72, wherein R¹ is heterocyclyl.
- 74. (Original) The compound of Claim 72, wherein R¹ is heteroalkyl.
- 75. (Original) The compound of Claim 72, wherein R¹ is hydroxyalkyl.
- 76. Currently Amended) A method for treating p38 mediated disorder arthritis, said method comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 60.
 - 77. (Canceled)

HALLR6 # 139547 v1

4

· R0085D CON